What medical breakthrough in January 2026 saw the FDA approve caplacizumab-yhdp as the first therapy for pediatric aTTP?

In January 2026, the U.S. Food and Drug Administration made a significant medical announcement by approving caplacizumab-yhdp, known commercially as Cablivi, as the first-ever treatment specifically for pediatric patients aged 12 years and older suffering from acquired thrombotic thrombocytopenic purpura (aTTP). This breakthrough offers a crucial new therapeutic option for a patient population with a rare and life-threatening blood disorder.

Acquired thrombotic thrombocytopenic purpura is an autoimmune condition where the body's immune system mistakenly attacks an enzyme called ADAMTS13, which is vital for regulating blood clotting. This deficiency leads to the formation of widespread, tiny blood clots in small blood vessels throughout the body, obstructing blood flow to essential organs such as the brain, heart, and kidneys. The condition also results in a dangerously low platelet count and the destruction of red blood cells. While rare in adults, aTTP is even more uncommon in children, affecting approximately one in ten million annually.

Before the approval of Cablivi, treatment for pediatric aTTP largely relied on approaches adapted from adult care, as no specific FDA-approved therapies existed for younger patients. Cablivi is a nanobody-based therapy that works by targeting the von Willebrand factor, a protein that plays a key role in platelet adhesion and clot formation in aTTP, thereby blocking its interaction with platelets and helping to reduce the harmful microvascular clots. This approval was supported by a retrospective study that demonstrated 80% of pediatric patients achieved clinical remission when Cablivi was used in combination with standard plasma exchange and immunosuppressive therapy. The ability of Cablivi to rapidly restore platelet counts and mitigate the risk of severe organ damage marks a substantial advancement in managing this devastating disease in children.